32,942 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by RPg Family Wealth Advisory LLC

RPg Family Wealth Advisory LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 32,942 shares of the biopharmaceutical company’s stock, valued at approximately $1,886,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Verdence Capital Advisors LLC increased its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 261 shares during the period. Private Advisor Group LLC lifted its position in shares of Halozyme Therapeutics by 1.8% in the 2nd quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 412 shares in the last quarter. Finally, Juncture Wealth Strategies LLC boosted its stake in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 415 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on HALO shares. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Piper Sandler upped their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total value of $590,900.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $39,988,802.96. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 60,000 shares of company stock valued at $3,425,000. Corporate insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $47.76 on Wednesday. The stock has a market capitalization of $6.08 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.43 and a beta of 1.29. The business has a 50-day moving average of $54.00 and a two-hundred day moving average of $53.71. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.